Bavarian Nordic A/S (Bavarian Nordic A/S) DeferredTaxAndRevenue

: $0 Mil (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Bavarian Nordic A/S's current deferred tax and revenue for the quarter that ended in Dec. 2023 was $0 Mil.

Bavarian Nordic A/S DeferredTaxAndRevenue Historical Data

The historical data trend for Bavarian Nordic A/S's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bavarian Nordic A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

DeferredTaxAndRevenue

Bavarian Nordic A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
DeferredTaxAndRevenue																-	-	-	-	-

Bavarian Nordic A/S DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Bavarian Nordic A/S's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Bavarian Nordic A/S (Bavarian Nordic A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bavarian Nordic A/S (OTCPK:BVNRY) » Definitions » DeferredTaxAndRevenue

Comparable Companies

Traded in Other Exchanges

BVNKF:USA BAVAc:UK 0DPB:UK BAVA:Denmark BV3:Germany

Address

Philip Heymans Alle 3, Hellerup, DNK, DK-2900

Website

https://www.bavarian-nordic.com

Bavarian Nordic A/S is a biotechnology company focused on the development, manufacturing, and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company has a specific focus on diseases for which the unmet medical need is high. Bavarian generates revenue through government research and development and supply contracts, and from its commercial partnerships. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets.